We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




C-Peptide Responsiveness May Explain HbA1c Variation

By LabMedica International staff writers
Posted on 24 Apr 2019
The addition of timing measures of C-peptide responsiveness may partly explain the glycated hemoglobin (HbA1c) level variation at diagnosis of type 1 diabetes (T1D) during the oral glucose tolerance test (OGTT).

Previous studies have reported C-peptide responsiveness changes during the progression to T1D, but there are no data regarding the timing of C-peptide responses at diagnosis and the association with glucose levels. More...
The goal of a new trial was to study whether timing of C-peptide responsiveness during test OGTT might explain variance in HbA1c levels at diagnosis of T1D.

Scientists at the Indiana University School of Medicine (Indianapolis, IN, USA) and their colleagues enrolled 85 patients age <18 years at diagnosis (mean age, 11.2 years; 51% boys) with complete OGTT data and HbA1c measurement at diagnosis. Peak C-peptide, area under the curve C-peptide, and measures of relative timing were recorded, including early C-peptide response, late C-peptide response, the 120-minute/30-minute C-peptide ratio, and time to peak C-peptide.

The team reported that there was an inverse correlation between HbA1c with measures of overall C-peptide responsiveness: area under the curve C-peptide and peak C-peptide. The inverse correlation was consistent with both early and late C-peptide responses and the 120-minute/30-minute C-peptide ratio. In 27 patients with a peak C-peptide at ≤60 minutes, HbA1c levels were higher compared with 58 participants with a peak C-peptide at >60 minutes. Similar to HbA1c, there was also inverse correlation between 2-hour glucose levels after OGTT with early and late C-peptide responses.

The authors concluded that their findings show that the addition of timing measures of C‐peptide responsiveness better explains HbA1c variation at diagnosis than standard measures alone. The study was published on March 20, 2019, in the journal Pediatric Diabetes.

Related Links:
Indiana University School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Automatic CLIA Analyzer
Shine i6000
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Graphical Abstract (Zeyang Shen et al., Shotgun Metagenomics Reveals Skin Microbiome Composition and Function in Infant Atopic Disease, Allergy, 2026. DOI: 10.1111/all.70449)

Infant Skin Microbiome Show Links to Later Eczema and Food Allergies

Eczema, or atopic dermatitis, and food allergies often begin in infancy and are among the earliest stages of the atopic march. Atopic dermatitis alone can affect up to 20% of children, yet objective indicators... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: Under the theme “From Tissue to Answer”, the launch of VisiOmics anchors a comprehensive pathology portfolio spanning tissue and molecular pathology (Photo courtesy of MGI Tech Co., Ltd.)

MGI Launches Automated Multiplex Tissue Staining and Imaging System at ECP 2026

MGI Tech Co., Ltd. (Shenzhen, China) introduced VisiOmics (PMIF-20RS), a fully automated multiplex immunofluorescence staining and imaging system, at the 38th European Congress of Pathology (ECP 2026)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.